ImmuPharma (LON:IMM) Trading 15% Higher - Should You Buy?

Key Points

• ImmuPharma shares surged by 15% on Thursday, reaching a high of GBX 13.85 ($0.19) before closing at GBX 13 ($0.18).
• The company reported a significant negative return on equity of -131.41%, with an earnings per share of GBX (0.38) for the last quarter.
• ImmuPharma specializes in developing peptide-based therapeutics for autoimmune diseases, notably its lead program Lupuzor™, aimed at treating Lupus.

ImmuPharma plc (LON:IMM - Get Free Report) shares rose 15% on Thursday . The company traded as high as GBX 13.85 ($0.19) and last traded at GBX 13 ($0.18). Approximately 13,221,054 shares traded hands during mid-day trading, an increase of 53% from the average daily volume of 8,639,387 shares. The stock had previously closed at GBX 11.30 ($0.15).

ImmuPharma Stock Up 3.2%

The business's 50-day simple moving average is GBX 5.71 and its 200 day simple moving average is GBX 3.70. The firm has a market capitalization of £67.06 million, a P/E ratio of -1,507.87 and a beta of 1.53.

ImmuPharma (LON:IMM - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported GBX (0.38) EPS for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. Sell-side analysts predict that ImmuPharma plc will post -339.0000022 earnings per share for the current year.

About ImmuPharma

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.